Randomized, Placebo-controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2)

Cocaine is one of the most commonly abused stimulants globally, and in the US,  there are signs of a resurgence of cocaine use. A variety of pharmacotherapies for cocaine use disorder (CUD) has been explored but so far, no study has findings robust enough to warrant FDA approval. Recent research suggests that a kappa opioid receptor antagonist can curb the negative emotional states associated with stimulant withdrawal that leads to increased craving and drug-seeking behaviors. This protocol builds up on results of the Cocaine Use Reduction with Buprenorphine (CURB) study. It aims to evaluate the safety and efficacy of combined monthly injections of XR-NTX and injectable BUP for CUD compared to placebo.

CTN Protocol ID: 
CTN-0109
Status: 
Development

Principal Investigator(s)

Madhukar H. Trivedi, M.D.

Betty Jo Hay Distinguished Chair in Mental Health Professor, Node Principal Investigator
University of Texas Southwestern Medical Center
Department of Psychiatry

5323 Harry Hines Boulevard
Dallas, TX 75390
United States

Steve Shoptaw, Ph.D.

Professor and Vice Chair for Research Department of Family Medicine
University of California, Los Angeles

10880 Wilshire Boulevard, Suite 1800
Los Angeles, CA 90024
United States